• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Innovative Eyewear Inc.

    4/17/25 4:04:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care
    Get the next $LUCY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Innovative Eyewear, Inc.

    (Name of Issuer)


    Common stock, par value $0.00001 per share

    (Title of Class of Securities)


    45791D208

    (CUSIP Number)


    04/11/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45791D208


    1Names of Reporting Persons

    Mitchell P. Kopin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    333,071.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    333,071.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    333,071.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    45791D208


    1Names of Reporting Persons

    Daniel B. Asher
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    333,071.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    333,071.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    333,071.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    45791D208


    1Names of Reporting Persons

    Intracoastal Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    333,071.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    333,071.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    333,071.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Innovative Eyewear, Inc.
    (b)Address of issuer's principal executive offices:

    11900 Biscayne Blvd., Suite 630, North Miami, Florida 33181
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.
    (c)Citizenship:

    Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
    (d)Title of class of securities:

    Common stock, par value $0.00001 per share
    (e)CUSIP No.:

    45791D208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Immediately following the execution of the inducement letter agreement with the Issuer on April 11, 2025 (the "Letter Agreement") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on April 15, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 271,059 shares of Common Stock, which consisted of (i) 265,000 shares of Common Stock to be issued to Intracoastal upon exercise of four warrants held by Intracoastal (collectively, the "Exercised Intracoastal Warrants") at the closing of the transaction contemplated by the Letter Agreement and (ii) 6,059 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the Letter Agreement ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 2,442,248 shares of Common Stock outstanding immediately prior to the execution of the Letter Agreement, as reported to the Reporting Persons by the Issuer, plus (2) 265,000 shares of Common Stock to be issued to Intracoastal upon exercise of the Exercised Intracoastal Warrants at the closing of the transaction contemplated by the Letter Agreement and (3) 6,059 shares of Common Stock to be issued to Intracoastal upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 19,344 shares of Common Stock in the aggregate issuable upon exercise of the Exercised Intracoastal Warrants because the Letter Agreement contains a blocker provision under which such shares of Common Stock shall be held in abeyance to the extent (but only to the extent) that the issuance of such shares of Common Stock would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 96,639 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (III) 829,282 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the Letter Agreement ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (IV) 4,721 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (V) 61,476 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 4") because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (VI) 61,476 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 5") because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,343,997 shares of Common Stock. (ii) As of the close of business on April 17, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 333,071 shares of Common Stock, which consisted of (i) 36,460 shares of Common Stock held by Intracoastal, (ii) 19,344 shares of Common Stock in the aggregate issuable under the Exercised Intracoastal Warrants, (iii) 102,698 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (iv) 174,569 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 2,442,248 shares of Common Stock outstanding immediately prior to the execution of the Letter Agreement, as reported to the Reporting Persons by the Issuer, plus (2) 595,188 shares of Common Stock in the aggregate issued at the closing of the transaction contemplated by the Letter Agreement, (3) 19,344 shares of Common Stock in the aggregate issuable under the Exercised Intracoastal Warrants, (4) 102,698 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (5) 174,569 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 654,713 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 4,721 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (III) 61,476 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (IV) 61,476 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,115,457 shares of Common Stock.
    (b)Percent of class:

    9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    333,071

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    333,071

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Mitchell P. Kopin
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin
    Date:04/17/2025
     
    Daniel B. Asher
     
    Signature:/s/ Daniel B. Asher
    Name/Title:Daniel B. Asher
    Date:04/17/2025
     
    Intracoastal Capital LLC
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin, Manager
    Date:04/17/2025
    Exhibit Information

    Exhibit 1 - Joint Filing Agreement

    Get the next $LUCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUCY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LUCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Innovative Eyewear Inc. Reports Q1 2025 Unaudited Financial Results

      Revenue and gross margins improvements MIAMI, May 13, 2025 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced its Q1 2025 Unaudited financial results. Net revenue for the quarter ended March 31, 2025 was $454,501 an increase of 19% from revenue of $383,471 in the quarter ended March 31, 2024. This increase was primarily attributable to growth in unit sales volume, largely driven by product launches during 2024 of the co-branded Nautica® Powered by Lucyd and

      5/13/25 5:49:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear Partners with Eye Recommend, Expanding Smart Eyewear Access Across 600+ Independent Optometry Stores

      MIAMI, May 5, 2025 /PRNewswire/ -- Innovative Eyewear, Inc. (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announces that it has partnered with Eye Recommend to provide its smart eyewear to more than 600 independent optical practices across Canada, significantly broadening accessibility of Innovative Eyewear's smart eyewear throughout the Canadian market. Buying groups like Eye Recommend serve an important function in the optical industry landscape, making it easier for independent optometrists to access

      5/5/25 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear Launches Reebok® Smart Eyewear

      MIAMI, April 28, 2025 /PRNewswire/ -- Innovative Eyewear Inc. (NASDAQ:LUCY), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced the launch of Reebok Smart Eyewear, available worldwide on Lucyd.co. Expanded availability is expected later this quarter on Reebok.com and select online and traditional retailers. A Landmark Product Launch The global smart glasses market is projected to reach approximately $13 billion worldwide by 20301. We believe Reebok Powered by Lucyd smart eyewear positions Innovative Eyewear at the forefr

      4/28/25 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Gayle Oswald

      3 - Innovative Eyewear Inc (0001808377) (Issuer)

      10/25/24 9:59:55 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $721,472 worth of shares (70,000 units at $10.31) and sold $148,896 worth of shares (14,037 units at $10.61) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 4:12:34 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $1,822,973 worth of shares (200,792 units at $9.08) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 2:41:40 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Innovative Eyewear, Inc. Signs Professional Football Player Emmanuel Ogbah as Brand Ambassador

      MIAMI, Dec. 14, 2023 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ:LUCY, LUCYW))), the developer of the developer of ChatGPT smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, is pleased to announce the signing of Emmanuel Ogbah as an official brand ambassador. Emmanuel Ikechukwu Ogbah is a Nigerian professional football defensive end for the Miami Dolphins. He played college football at Oklahoma State and was drafted by the Cleveland Browns in the second round of the 2016 NFL Draft. Lucyd eyewear's open-ear au

      12/14/23 8:30:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Innovative Eyewear Inc.

      10-Q - Innovative Eyewear Inc (0001808377) (Filer)

      5/13/25 4:30:26 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • SEC Form S-1 filed by Innovative Eyewear Inc.

      S-1 - Innovative Eyewear Inc (0001808377) (Filer)

      5/9/25 4:05:44 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • SEC Form SCHEDULE 13G filed by Innovative Eyewear Inc.

      SCHEDULE 13G - Innovative Eyewear Inc (0001808377) (Subject)

      4/17/25 4:04:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Galkin Vladimir bought $721,472 worth of shares (70,000 units at $10.31) and sold $148,896 worth of shares (14,037 units at $10.61) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 4:12:34 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $1,822,973 worth of shares (200,792 units at $9.08) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 2:41:40 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $2,649,148 worth of shares (297,443 units at $8.91) and sold $384,100 worth of shares (42,328 units at $9.07) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 2:40:55 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Innovative Eyewear Inc.

      SC 13G/A - Innovative Eyewear Inc (0001808377) (Subject)

      11/13/24 11:18:48 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Innovative Eyewear Inc.

      SC 13D/A - Innovative Eyewear Inc (0001808377) (Subject)

      10/4/24 4:43:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Innovative Eyewear Inc.

      SC 13D/A - Innovative Eyewear Inc (0001808377) (Subject)

      9/25/24 4:17:38 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Financials

    Live finance-specific insights

    See more
    • Innovative Eyewear Inc. Reports Third Quarter 2024 Financial Results

      Revenue Increased 14% in Q3 2024 vs Q3 2023, and 76% on a Year-to-Date Basis vs 2023 MIAMI, Nov. 13, 2024 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), a developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced its financial results for the third quarter of 2024. Net revenue for the quarter ended September 30, 2024 was $253,599, an increase of 14% from the quarter ended September 30, 2023. This year-over-year increase was primarily attributable to strategic reductions in price discounts and other adjustments to o

      11/13/24 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear, Inc. Adopts Limited Duration Stockholders Rights Plan

      MIAMI, Sept. 25, 2024 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq: LUCY), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one right ("Right") for each outstanding share of common stock. The record date for such dividend distribution is September 25, 2024. The Rights Plan expires, without any further action being required to be taken by Innovative Eyewear's Board of Directors, on September 25, 2025 or at such earlier time as disclos

      9/25/24 8:20:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear Inc. Reports Second Quarter 2024 Financial Results

      Quarterly Revenue Increased 82% vs Q2 2023; Gross Margin Increases Substantially MIAMI, Aug. 13, 2024 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW))), the developer of ChatGPT-enabled smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced its financial results for the second quarter of 2024. Net revenue for the quarter ended June 30, 2024 was $308,682, an increase of 82% from the quarter ended June 30, 2023. Net revenue for the six months ended June 30, 2024 was $692,153, an increase of 120% vs. the comparable period in 2023.

      8/13/24 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care